Categorisation of Patients' Anticholinergic Burden at Admission and Discharge from the Geriatric Ward of Sønderjylland Hospital.

IF 2 Q3 PHARMACOLOGY & PHARMACY Pharmacy Pub Date : 2024-10-25 DOI:10.3390/pharmacy12060160
Cecilie Marie Bæk Kehman, Maja Schlünsen, Lene Juel Kjeldsen
{"title":"Categorisation of Patients' Anticholinergic Burden at Admission and Discharge from the Geriatric Ward of Sønderjylland Hospital.","authors":"Cecilie Marie Bæk Kehman, Maja Schlünsen, Lene Juel Kjeldsen","doi":"10.3390/pharmacy12060160","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>High anticholinergic burden is associated with an increased risk of hospitalisation, readmission, and mortality in geriatric patients. The objectives were to develop an updated anticholinergic burden scale for drugs registered in Denmark and to estimate the burden at admission and discharge for hospitalised patients at the Geriatric Ward of Sønderjylland Hospital.</p><p><strong>Methods: </strong>The updated scale was developed through a systematic evaluation of the anticholinergic effect for all active pharmaceutical ingredients (APIs) listed on validated burden scales. APIs registered in 2020 and 2021 were evaluated separately for possible anticholinergic effect. The anticholinergic effect of each API was scored from 1 (low) to 3 (high). The scale was applied to medical records for patients hospitalised between October 2021 and March 2022.</p><p><strong>Results: </strong>The scale comprised 87 APIs with anticholinergic effect. We applied the scale on 196 patients aged (median [IQR]) 84 (78-89) years. Of these patients, 75 (38.3%) had a high burden (≥3) on admission. These patients had significantly higher drug use and higher risk of 30-day readmission but no relationship with length of stay. Overall, the anticholinergic burden was unchanged at discharge for 109 (55.1%) patients.</p><p><strong>Conclusion: </strong>An updated scale for estimation of the anticholinergic burden in geriatric patients was successfully developed, and a high burden among the admitted geriatric patients was found.</p>","PeriodicalId":30544,"journal":{"name":"Pharmacy","volume":"12 6","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587422/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/pharmacy12060160","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: High anticholinergic burden is associated with an increased risk of hospitalisation, readmission, and mortality in geriatric patients. The objectives were to develop an updated anticholinergic burden scale for drugs registered in Denmark and to estimate the burden at admission and discharge for hospitalised patients at the Geriatric Ward of Sønderjylland Hospital.

Methods: The updated scale was developed through a systematic evaluation of the anticholinergic effect for all active pharmaceutical ingredients (APIs) listed on validated burden scales. APIs registered in 2020 and 2021 were evaluated separately for possible anticholinergic effect. The anticholinergic effect of each API was scored from 1 (low) to 3 (high). The scale was applied to medical records for patients hospitalised between October 2021 and March 2022.

Results: The scale comprised 87 APIs with anticholinergic effect. We applied the scale on 196 patients aged (median [IQR]) 84 (78-89) years. Of these patients, 75 (38.3%) had a high burden (≥3) on admission. These patients had significantly higher drug use and higher risk of 30-day readmission but no relationship with length of stay. Overall, the anticholinergic burden was unchanged at discharge for 109 (55.1%) patients.

Conclusion: An updated scale for estimation of the anticholinergic burden in geriatric patients was successfully developed, and a high burden among the admitted geriatric patients was found.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Sønderjylland 医院老年病房患者入院和出院时抗胆碱能药物负担的分类。
背景:高抗胆碱能药物负担与老年病人住院、再次入院和死亡风险增加有关。我们的目标是为在丹麦注册的药物制定最新的抗胆碱能负担量表,并估算森德吉兰德医院老年病区住院病人入院和出院时的抗胆碱能负担:更新后的量表是通过对有效负担量表中列出的所有活性药物成分(API)的抗胆碱能效应进行系统评估而制定的。对 2020 年和 2021 年注册的原料药分别进行了可能的抗胆碱能效应评估。每种原料药的抗胆碱能效应从 1 分(低)到 3 分(高)不等。该量表适用于 2021 年 10 月至 2022 年 3 月期间住院患者的医疗记录:该量表包括87种具有抗胆碱能作用的原料药。我们对年龄(中位数[IQR])为 84(78-89)岁的 196 名患者使用了该量表。在这些患者中,75 人(38.3%)在入院时药物负担较重(≥3)。这些患者的用药量明显较高,30 天再入院的风险也较高,但与住院时间没有关系。总体而言,109 名(55.1%)患者出院时的抗胆碱能药物负担没有变化:结论:成功开发了用于估算老年病人抗胆碱能药物负担的最新量表,并发现入院老年病人的抗胆碱能药物负担较高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacy
Pharmacy PHARMACOLOGY & PHARMACY-
自引率
9.10%
发文量
141
审稿时长
11 weeks
期刊最新文献
Attitudes and Experiences of Patients Regarding Gender-Specific Aspects of Pain Management. Assessment of Potential Drug-Drug Interactions of Psycholeptics and Antidepressants in Outpatient Settings. Tackling Pharmaceutical Pollution Along the Product Lifecycle: Roles and Responsibilities for Producers, Regulators and Prescribers. Evaluating Pharmacists' Knowledge of Food-Drug Interactions in Croatia: Identifying Gaps and Opportunities. Cardiovascular Diseases and Metabolic Medications in the Lebanese Population: A Post Hoc Analysis from a Nationwide Cross-Sectional Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1